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INTRODUCTION
Epithelial ovarian cancer (EOC) is the leading cause of gy-
necologic cancer death in Western countries [1]. Despite 
standardized treatment consisting of cytoreductive surgery 
followed by platinum-based systemic chemotherapy, the 
prognosis of patients with advanced ovarian cancer is poor 
and the majority of them experience recurrences [2,3]. As a 
result, there has been considerable interest in developing 
predictive markers to assess the risk of a relapse in advanced 
EOC patients. The most famous biomarker in EOC is CA-125, 
which has been used in both diagnosis of the disease and 
monitoring of treatment [4-6]. Recent evidence indicates that 
the nadir CA-125 level after completion of primary treatment 
was associated with prognosis [7-11]. Though the use of prog-
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Objective: We aimed to determine the ideal cut-off of nadir serum CA-125 level for prediction of progression free survival.
Methods: Among 267 patients who achieved complete remission after chemotherapy, the correlation between nadir CA-125 
and progression free survival were compared among the subgroups classified according to the distribution of CA-125. The 
diagnostic odds ratio and area under the receiver operator characteristics curve were compared at various cut-off points.
Results: The nadir CA-125 levels did not have prognostic value under 12 U/mL (to 75 percentile). In contrast, they were 
significantly correlated with progression free survival only when the CA-125 level was greater than 12, which was 75 percentile 
(p=0.034). In predicting progression free survival <6 and 12 months, the cut-off value of 18 (90 percentile) showed superior 
diagnostic performance over 10 or 12 U/mL. Compared with patients who showed nadir levels between 0 and 12 U/mL (0 to 75 
percentile), those with nadir >18 U/mL showed a hazard ratio of 2.85 (95% confidence interval, 1.70 to 4.76; p<0.001); patients 
with nadir levels between 18 and 12 U/mL showed a the hazard ratio of 1.68 (95% confidence interval, 1.11 to 2.56; p=0.015) 
compared with those whose nadir levels were under 12 U/mL.
Conclusion: The predictive power of the traditional cut-off of 10 U/mL to classify a risk group or to identify high risk patients 
was unsatisfactory. The optimal diagnostic performance was observed at the cut-off of 18 U/mL and this can be proposed to 
dichotomize cut-off values to predict outcomes among individual patients.
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nostic information is not well studied, some have proposed 
its possible role in the stratification of patients in clinical trials 
and planning further treatment [9,10].
Many researchers have usually used the cut-off value of 10 
and/or 20 U/mL [7,9-11]. Some suggested 12 U/mL as a cut-off 
value based on the median CA-125 level of their study cohort 
[8]. However, there was still no consensus about the proper 
cut-off value of nadir CA-125 that can discriminate patients 
with better prognosis from those with poorer outcome. If we 
should stratify the trial group or plan a novel consolidation 
treatment to improve the outcome of the poor prognostic 
group, what cut-off value should we adopt for discriminating 
the patients? Can we classify patients with a nadir level of 10.5 
as belonging to an unfavorable group, while classify others 
with a nadir level of 9.5 as favorable? The current study was 
designed to answer this question and to provide a possible 
algorithm to determine a non-arbitrary cut-off value of nadir 
CA-125. Here, we show the discrimination performance at 
various cut-off level of nadir CA-125 which help to determine 
the ideal cut-off value of post-operative CA-125 in order to 
discriminate between high- and low-risk groups.
MATERIALS AND METHODS
From two institutions, the National Cancer Center (Goyang, Ko-
rea) and the Samsung Medical Center (Seoul, Korea), we iden-
tified 436 patients who had undergone surgery for advanced 
(stage III or IV) EOC between January 2001 and December 
2007, consecutively. Institutional review board approval was 
exempted because the patient information was de-identified. 
All patients treated at the institution during that time period 
were included in the analysis; those with borderline tumors 
were excluded. The inclusion criteria were as follows: 1) serum 
CA-125 levels at the time of diagnosis >35 U/mL, 2) clinical, 
biochemical (post-treatment serum CA-125 ≤35 U/mL) and ra-
diologic complete remission (CR), and 3) available records for 
CA-125 levels at the time of diagnosis and at its nadir. The pre-
treatment CA-125 level was required to be reported within 
4 weeks from the time of diagnosis. The post-treatment CA-
125 level was required to be reported after 2 weeks but within 
4 weeks from the end of chemotherapy. To determine nadir 
CA-125 levels, at least two serial serum CA-125 level determi-
nations with at least 2 weeks interval were required within 4 
months following the end of treatment. With these inclusion 
criteria, 267 patients were finally selected for the analysis. The 
data from these patients were used in a previous publication 
by our group [11].
The medical records of these patients were reviewed and 
the following information were collected: age at diagnosis, 
tumor grade and histology, tumor stage, serum CA-125 levels 
at the time of diagnosis, optimality of cytoreductive surgery, 
nadir serum CA-125 concentration, and timing of recurrence 
and/or disease status at the last follow-up. The serum CA-125 
level was determined with a radioimmunoassay. No central-
ized measurement was applied. All patients were surgically 
staged according to the International Federation of Gynecol-
ogy and Obstetrics (FIGO) system. Optimal cytoreduction was 
defined as no residual tumor measuring ≥1 cm in the maximal 
dimension at the completion of the surgical procedure. After 
surgery, all patients received adjuvant chemotherapy with car-
boplatin (area under the curve of 5) and paclitaxel (175 mg/
m
2) for six to nine cycles. When a patient is in poor medical 
condition or when preoperative radiologic imaging suggests 
unsuccessful optimal surgery, neoadjuvant chemotherapy 
based on carboplatin and paclitaxel was administered based 
on the clinician’s decision.
The progression-free survival (PFS) was the primary end-
point, and was defined as the interval between the date of 
initial treatment until the last date of follow-up, or the date of 
recurrence. After CR, all the patients were followed-up with an 
interval of less than 3 months. Serum CA-125 was obtained at 
each visit. Disease recurrence was defined as the appearance 
of a new lesion, or the reappearance of any lesion that had 
disappeared on diagnostic imaging (computed tomography 
[CT] and magnetic resonance imaging [MRI]).
All statistical analyses were performed using STATA ver. 10.0 
(College Station, TX, USA). The survival distributions were 
estimated by the Kaplan-Meier method, and statistical signifi-
cance was determined by the log-rank test and Cox’s propor-
tional hazard model analysis. The formula for a positive likeli-
hood ratio (LR) is sensitivity/(1-specificity), and the formula for 
a negative LR is (1-sensitivity)/specificity. A clinically useful test 
was defined as having a positive LR >5.0 and a negative LR 
<0.2. All p-values presented were two-sided, and associations 
were considered significant if the p-value was <0.05. 
RESULTS
The clinical and pathological characteristics of 267 patients 
are summarized in Table 1. The median age was 55 years and 
59.6% of the patients had optimal cytoreduction during their 
surgery. The median follow-up time was 41.9 months and the 
median PFS was 21.2 months (95% confidence interval [CI], 
18.0 to 22.9 months). The patients who had nadir CA-125 lev-
els under 10 U/mL showed significantly better survival com-
pared with patients with nadir between 10 and 35 U/mL (log Nadir serum CA-125 and ovarian cancer
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rank test, p=0.0001).
The distribution of nadir CA-125 level is shown in Fig. 1A. 
It showed a skewed distribution. Nadir CA-125 levels from 
half of the patients were located between 7.3 and 12.1 U/mL. 
Therefore, we calculated the logarithm of CA-125 and the cor-
responding distribution (Fig. 1B). In all Cox’s hazard models 
of the current study, the logarithm transformation was ap-
plied for nadir CA-125 level. Then, we divided the patients by 
median level of nadir CA-125, which is 9.3 U/mL. As expected, 
we observed that PFS was strongly correlated with nadir CA-
125 levels (p=0.002) (Fig.1C). Next, we divided the group by 
25, 50, and 75 percentiles of nadir CA-125 (7.3, 9.3, and 12.1 U/
mL) and tested the difference in PFS among the four groups. 
Interestingly, the PFS of the 50-75 percentile group was not 
different from that of the 25-50 percentile group, and even 
from that of the 0-25 percentile group. However, only the 75-
Fig. 1. Logarithm transformation of nadir CA-125 levels and estimation of progression free survival function using Kaplan-Meyer curve. (A) Skewed 
distribution of nadir CA-125 levels. (B) After logarithm transformation, distribution of nadir CA-125 levels showed normal distribution. (C) Kaplan-
Meyer survival curve showed significant difference of progression free survival between patients with nadir CA-125<10 U/mL and ≥10 U/mL (Log rank 
test, p=0.002). (D) The progression free survival of the patients within 50-75 percentile is not different from the group within 0-50 percentile. However, 
only the patients over 75 percentile showed significant difference of progression free survival according to nadir CA-125 levels (p<0.001).
Table 1. Characteristics of 267 advanced epithelial ovarian cancer 
pa  tients who achieved complete remission and had initially elevated 
serum CA-125 levels
Characteristics Values





FIGO stage III 233 (87.3)
FIGO stage IV 34 (12.7)
Initial CA-125 levels (U/mL) 1,129 (35.3-33,270)
Residual tumor size
Less than 1 cm (optimal) 159 (59.6)
1 cm or more (suboptimal) 108 (40.4)
Values are presented as median (range) or number (%).Sokbom Kang, et al.
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100 percentile group showed significantly different PFS from 
the other groups (p<0.001) (Fig. 1D). Then, we compared the 
hazard ratios in order to show that nadir CA-125 was a weak 
predictor among the 25-75 percentile group (Table 2). We 
tested age, histology, stage, initial CA-125 level, optimality of 
cytoreduction as predictors, and age and optimality of cyto-
reduction were found to be significant predictors for multi-
variate analysis. The logarithm of nadir CA-125 level was not 
associated with hazard ratio within each group except for the 
75-100 percentile group (p=0.034).
Based on the above observations, we tested the diagnos-
tic performance of several provisional cut-off values of nadir 
CA-125 (10, 12 and 18 U/mL) in predicting PFS at 6 and 12 
months (Table 3). In the prediction of PFS <6 months and <12 
months, the cut-off value of 18 U/mL showed the highest ac-
curacy (89.2% and 80.8%, respectively), while accuracy was 
lowest in the cut-off level of 10 U/mL. If we may weigh the 
predicting power of the high-risk group greater than classifi-
cation accuracy, positive LR and specificity should be of inter-
est. Again, the cut-off value of 18 U/mL showed the highest 
positive LR and specificity in prediction of PFS <6 months and 
<12 months. As a result, the cut-off of 18 U/mL showed the 
highest positive predictive value in predicting both end points 
(28.6% and 52.0%, respectively).
Finally, we classified the study cohort into three groups at 
the cut-off of 12.1 U/mL (75 percentile) and 18.1 U/mL (90 
percentile) and performed multivariate Cox analysis (Table 4). 
The FIGO stage was not included in the multivariate analysis 
because it did not show significant association in univariate 
analysis (p=0.742). In multivariate analysis, the current data 
were unable to detect an association between optimal cytore-
Table 2. Multivariate Cox’s proportional hazard model of progression free survival within the subgroups classified according to the nadir CA-
125 levels
Nadir CA-125 levels Covariates Hazard ratio (95% CI)* p-value
0-25 percentile (n=67) Optimal cytoreduction 2.99 (1.44-6.22) 0.003
Log (nadir CA-125) 1.85 (0.62-5.54) 0.269
25-75 percentile (n=134) Optimal cytoreduction 1.17 (0.73-1.87) 0.524
Log (nadir CA-125) 1.94 (0.38-9.81) 0.422
75-100 percentile (n=66) Optimal cytoreduction 0.94 (0.49-1.78) 0.842
Log (nadir CA-125) 3.28 (1.10-9.83) 0.034
CI, confidence interval.
*All models was adjusted by age at the time of diagnosis and optimal debulking status (residual mass <1 cm).




Accuracy (%) Positive LR Specificity (%) PPV (%)
Prediction of PFS < 6 mo
10 (Reference) 61.2 1.9 60.2 11.0
12 (75 percentile) 76.5 3.0 77.0 16.4
18 (90 percentile) 89.2 6.1 91.8 28.6
Prediction of PFS < 12 mo
10 (Reference) 66.4 2.0 66.2 32.7
12 (75 percentile) 74.8 2.6 81.1 38.7
18 (90 percentile) 80.8 4.4 94.0 52.0
LR, likelihood ratio; PPV, positive predictive value; PFS, progression free survival.
Table 4. Cox proportional hazard model of progression free survival 




Age at the time of diagnosis 1.01 (0.99-1.02) 0.306
Optimal cytoreduction 1.29 (0.94-1.77) 0.117
Nadir CA-125 levels
0 to 75 percentile (0-12.1 U/mL) 1.00 -
75 to 90 percentile (12-18.1 U/mL) 1.68 (1.11-2.56) 0.015
90 to 100 percentile (18.1-35.0 U/mL) 2.85 (1.70-4.76) <0.001
CI, confidence interval.Nadir serum CA-125 and ovarian cancer
J Gynecol Oncol Vol. 22, No. 4:269-274 www.ejgo.org 273
duction and outcome (p=0.117). The hazard ratio was signifi-
cantly higher in the 75-90 percentile group (1.68; 95% CI, 1.11 
to 2.56) and in the 90-100 percentile group (2.85; 95% CI, 1.70 
to 4.76) when they were compared with the 0-75 percentile 
group.
DISCUSSION
Based on previous evidence [7-11], it is clear that the post-
treatment nadir CA-125 level is a good predictor of PFS of 
EOC. Interestingly, many studies have used an arbitrary cut-
off value or a median value for the stratification of the cohort 
[7,9-11], but not a cut-off value determined on the basis of its 
diagnostic performance. In contrast to data of previous stud-
ies, the strength of our data is that the cut-off value has been 
tested with their diagnostic performance and area under the 
ROC curve. Moreover, we analyzed the distribution of the 
nadir value of CA-125 and determined the interval where the 
nadir level provided a prognostic value.
The current study revealed interesting features of the nadir 
CA-125 levels in patients who achieved CR. First, a large pro-
portion of the patients who achieved CR had nadir CA-125 
levels around 10 U/mL. Our data showed that the log-trans-
formed nadir CA-125 levels in patients with CR had a normal 
distribution and that half of the patients had their nadir CA-
125 levels between 7.3 and 12.1 U/mL. Thus, it is evident that 
dichotomization using a cut-off value near the median may 
result in inaccurate classification. Indeed, our data indicated 
that the nadir CA-125 level provided little prognostic informa-
tion in the interval between 7.3 and 12.1 U/mL. In contrast, 
the nadir CA-125 level had a prognostic value only when it fell 
between 12.1 and 35 U/mL. 
Second, we showed that the conventional cut-off of 10 U/
mL did not provide reliable diagnostic performance. In the 
prediction of PFS at given time points (6 and 12 months), it 
showed inferior performance, both in classification accuracy 
and reliability of screening high-risk patients. Indeed, there 
were conflicting data among several prospective cohorts 
about the differences in PFS between a group with nadir of 
0-10 U/mL and that with 10-20 U/mL [9,12]. Rather, our data 
showed that 18 U/mL was the better cut-off value. Although 
we can only identify 10% of the patients who achieved CR as 
being in the high-risk group, it has high specificity and a bet-
ter positive LR compared with other suggested cut-off values. 
If we may sacrifice accuracy for the inclusion of more high-risk 
patients, 12 U/mL should be the next choice. However, it is 
arguable that our results are valid for the current dataset and 
might not be generalized. Thus, our data should be validated 
in an external dataset.
In summary, the conventional cut-off of 10 U/mL should not 
be recommended in guiding treatment decisions or stratify-
ing patients because 1) the centralized distribution of nadir 
CA-125 around the median value may result in considerable 
misclassification; 2) its overall diagnostic performance is not 
satisfactory; and 3) when the nadir CA-125 value is near the 
median value, the correlation between CA-125 and survival 
outcome is not significant. Although either cut-off value of 10 
or 12 U/mL may show statistically significant correlation with 
PFS, the current study states that it does not provide clinically 
useful information in dichotomization or stratification of pa-
tients. Considering the positive LR and accuracy, we suggest 
18 U/mL as the optimal cut-off value of nadir CA-125 that can 
be used to identify high-risk patients with moderate reliability.
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